Ajanta Pharma Q4FY22 PAT lower by -5.05% at Rs151.21 crore on higher raw material and manpower costs

12 May 2022 , 01:31 AM

Ajanta Pharma Ltd reported 14.99% growth in sales revenues yoy for the Q4FY22 quarter on consolidated basis at Rs870.29 crore. On a sequential basis, revenues were higher for the quarter by 3.86%.

For the full year FY22, the revenues were higher by 15.6% at Rs3,341 crore. For Q4FY22, For the fourth quarter, India sales was up 13% at Rs245 crore, while full year India sales were up 21%.

Ajanta witnessed growth across verticals which included 11% in cardiology, 25% in ophthalmology, 17% in dermatology and 28% in pain management segment.

Pain management has been one of the fast growing segments of late.

The consolidated net profit for Q4FY22 was down -5.05% at Rs151.21 crore while it was down on a sequential basis by -21.15%.

The pressure on profits came from a spike raw material and from manpower costs. For Q4, the EBITDA fell from Rs259 crore to Rs207 crore on a yoy basis. EBITDA margins also tapered to 24% in the quarter.

Exports sales in the fourth quarter stood at Rs616 crore, led by EMs. Net margins stood at 17.37% in Q4FY22 compared to 21.04% in Q4FY21. NPM was lower sequentially against 22.89% in Q3FY22.

Financial highlights for Mar-22 compared yoy and sequentially

	Ajanta Pharma
Rs in Crore	Mar-22	Mar-21	YOY	Dec-21	QOQ
Total Income (Rs cr)	₹ 870.29	₹ 756.84	14.99%	₹ 837.91	3.86%
Net Profit (Rs cr)	₹ 151.21	₹ 159.26	-5.05%	₹ 191.78	-21.15%
Diluted EPS (Rs)	₹ 17.70	₹ 18.40		₹ 22.16
Net Margins	17.37%	21.04%		22.89%